

## **CURRICULUM VITAE of Dr. LI FANGFEI**

**Name:** LI FANGFEI

**Academic qualifications:**

2003-2007: B. Sc. Ocean University of China, Qingdao, China  
2007-2009: M. Sc. Ocean University of China, Qingdao, China  
2009-2013: Ph.D. University of New South Wales, Australia

**Previous academic positions held:**

2014-2015: Post-doctoral Research Fellow, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China  
2015~2016: Post-doctoral Research Fellow, Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR

**Present academic position:**

2016~now: Research Assistant Professor, Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR

**Previous relevant research work:**

- Technical expertise: Biochemistry, Molecular pharmacology
- Research area: Targeted drug delivery for anticancer and antimicrobial therapies.

**Publication records:**

**Section A Five most relevant publications in the recent five years**

1. Liang C, **Li F**, Wang L, Zhang ZK, Wang C, He B, Li J, Chen Z, Shaikh AB, Liu J, Wu X, Peng S, Dang L, Guo B, He X, Au DWT, Lu C, Zhu H, Zhang BT, Lu A, Zhang G. ‘Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma.’ *Biomaterials* 2017; 147,68.
2. **Li F**, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang Z-K, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang B-T, Lu A, Zhang G. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. *Nat. Commun.* 2017; DOI: 10.1038/s41467-017-01565-6.
3. Wang L, **Li F**, Dang L, Liang C, Wang C, He B, Liu J, Li D, Wu X, Xu X, Lu A, Zhang G, ‘*In Vivo* Delivery Systems for Therapeutic Genome Editing.’ *Int J Mol Sci.* 2016; 17, 626.
4. Shaikh AB, **Li F**, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, Zheng S, Liang C, Liu J, Lu C, Liu B, Lu J, Wang L, Lu A, Zhang G. ‘Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.’ *Int J Mol Sci.* 2016, 17, 506

5. **Li F**, J. G. Collins, F. R. Keene, 'Ruthenium complexes as antimicrobial agents.' *Chem. Soc. Rev.*, 2015, 44, 2529-42.

**Section B - Five representative publications beyond the recent five-year period with the latest publication entered first**

1. **Li F**, Mulyana Y, Feterl M, Warner J M, Collins J G, Keene F R, 'The antimicrobial activity of inert oligonuclear polypyridylruthenium(II) complexes against pathogenic bacteria, including MRSA' *Dalton Trans.*, 2011, 40(18), 5032-8.

**Patent**

1. F. R. Keene, J. G. Collins, J. M. Warner, **Li F**, K. Heimann, Y. Mulyana, M. Feterl, 'Antimicrobial Agents', filed on 21/12/2011 with the Australian (2011265513), USA (13/334741) and Canadian (2762717) Patent Offices.